Marleen van den Horst

T: +31 70 376 06 21
View Marleen van den Horst on LinkedIn

Marleen van den Horst is partner in the IP and Technology practice group and heads the industry group Healthcare and Life Sciences. Marleen has more than 25 years of experience in conducting complex, cross-border proceedings on intellectual property. Specialised in patent law, she handles cases involving mechanical engineering, electrical engineering, chemistry and life sciences. From ship shutters, electronic Braille cells, floating solar panels, telecoms UMTS and LTE standard essential patents , machines for the manufacture of PVC-O pipes to medical equipment and pharmaceuticals. Marleen has achieved international recognition in the field of Life Sciences. In recent years, she has litigated and advised on patent and administrative litigation concerning, among other things, drugs whose active ingredients are ciclosporin, (es)omeprazole alendronate, escitalopram, modafinil, tramadol/paracetamol, glatiramer acetate, trastuzumab, zoledronate, rivastigmine, lenalidomide, ezetimibe+simvastatin, dasatinib, pemetrexed and sitagliptin as well as on CRISPR-Cas9 technology. Aside from litigation, Marleen also assists clients in negotiating and drawing up licences, technology transfers and distribution and cooperation agreements.

Selected directory listings

Van den Horst has a similar penchant for advanced technologies and complicated cases, particularly in the life sciences. “In addition to the expertise she brings, I am also very impressed by the quality of Marleen’s efforts and her motivation to continuously support us in realising our dream,” reports one client. “We fought our case in multiple jurisdictions and Marleen’s defence was tried, tested and true.”IAM Patent 1000, 2021

Marleen van den Horst is recognized as Leading Individual in the area of Healthcare & Life sciences, It’s great to work with lawyers who not only have top legal insight and knowledge, but also a genuinely commercial approach’. – Legal 500, 2021

“Marleen van den Horst is highly skilled and highly experienced. She is deeply engaged in the cases handled by her team, stimulating excellence. Her team has a strong “can-do” approach.’ ‘Marleen van den Horst is incredibly well connected and respected, a skillful strategist and great person to work with’.”Legal 500, 2021

“Marleen Van den Horst routinely assists a clientele drawn from the pharmaceutical industry with patent infringement and invalidity cases. Clients rate the direction she brings to projects, one suggesting that “she is well organised and able to strategise cases well.”Chambers Global & Europe, 2021

“She pushes forward energetically and is always ready to pursue unconventional approaches if they look promising.”IAM Patent 1000, 2020

Marleen Van Den Horst has a well-established expertise in generic pharmaceuticals and is a ‘highly skilled litigator’ with ‘creative and commercially sound suggestions’” – Legal 500, 2020

“Marleen Van den Horst is praised by clients for maintaining a ‘really good oversight’ of cases. Her practice centres on contentious patent cases, where she frequently represents multinational pharmaceutical clients.” – Chambers Global & Europe, 2020

Professional activities

  • Marleen is a board member of the NeoKidney Foundation for the realization of a wearable artificial kidney. She provides pro bono advice on patent and other legal issues.
  • Marleen is a member of several professional organizations and trade associations, such as EPLAW, AIPPI, LES, VF&R and VIEPA.
  • She is frequently asked as a speaker at international conferences, such as ERA’s annual EU Pharmaceutical law Conference, Fordham University’s annual IP Conference, World IP Forum, LESI and EPLAW.

Recently from this specialist

Pharma update – 17 August 2021 | Provisions judge denies preliminary order to carve out indications from marketing authorisation adalimumab biosimilar

In his decision of 16 July 2021 (published 5 August 2021) the Provisions Judge of the District Court of Amsterdam denied a preliminary order claimed by AbbVie Biotechnology Ltd (“AbbVie”) against Alvotech HF, Alvotech Swiss AG and Stada Arzneimittel AG (“Stada”) (collectively: “Alvotech et al.”) to carve-out AbbVie’s patented indications prior to launching their biosimilar
Read more ›

Telecoms update | District Court rejects infringement claim

On 30 December 2020 (published 13 January 2021), the District Court of The Hague (“the Court”) rendered a judgment in final relief proceedings initiated by Adaptive Spectrum and Signal Alignment, Incorporated (“ASSIA”) against Koninklijke KPN N.V., Telfort Zakelijk B.V., XS4ALL Internet B.V., KPN B.V. (collectively “KPN”) and Nokia Solutions and Networks Nederland B.V. (“Nokia”) regarding
Read more ›

Pharma update | Dutch Court of Appeal: Pemetrexed patent Eli Lilly valid and infringed

In its judgment of 27 October 2020, the Court of Appeal of The Hague found that the generic pemetrexed tromethamine product of Fresenius Kabi Nederland B.V. (“Fresenius”) infringes EP 1 313 508 (‘EP‘508’), held by Eli Lilly and Company (“Lilly”). Yet again a turn of events in Dutch case law, where this issue has been
Read more ›
More from this specialist